Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Molecular Partners stock

MOLN.SW
CH0256379097
A12DEH

Price

5.39
Today +/-
+0.29
Today %
+5.14 %
P

Molecular Partners stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Molecular Partners stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Molecular Partners stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Molecular Partners stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Molecular Partners's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Molecular Partners Stock Price History

DateMolecular Partners Price
11/1/20245.39 undefined
10/31/20245.12 undefined
10/30/20245.45 undefined
10/29/20245.60 undefined
10/28/20245.79 undefined
10/25/20245.74 undefined
10/24/20245.52 undefined
10/23/20245.06 undefined
10/22/20245.80 undefined
10/21/20245.70 undefined
10/18/20244.45 undefined
10/17/20244.23 undefined
10/16/20244.25 undefined
10/15/20244.20 undefined
10/14/20244.29 undefined
10/11/20244.10 undefined
10/10/20244.19 undefined
10/9/20244.18 undefined
10/8/20244.33 undefined
10/7/20244.10 undefined

Molecular Partners Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Molecular Partners, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Molecular Partners from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Molecular Partners’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Molecular Partners. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Molecular Partners’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Molecular Partners’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Molecular Partners’s growth potential.

Molecular Partners Revenue, EBIT and net profit per share

DateMolecular Partners RevenueMolecular Partners EBITMolecular Partners Net Income
2030e361.52 M undefined187.05 M undefined131.45 M undefined
2029e218.08 M undefined135.97 M undefined14.6 M undefined
2028e82.57 M undefined-49.96 M undefined-43.82 M undefined
2027e45.8 M undefined-68.69 M undefined-63.9 M undefined
2026e20.06 M undefined-75.79 M undefined-72.71 M undefined
2025e7.48 M undefined-78.54 M undefined-75.71 M undefined
2024e5.78 M undefined-68.34 M undefined-66.13 M undefined
20237.04 M undefined-61.11 M undefined-61.98 M undefined
2022189.6 M undefined116.61 M undefined117.85 M undefined
20219.75 M undefined-63.42 M undefined-63.79 M undefined
20209.34 M undefined-58.33 M undefined-62.76 M undefined
201920.38 M undefined-36.66 M undefined-36.29 M undefined
201810.36 M undefined-37.41 M undefined-37.04 M undefined
201720.02 M undefined-25.84 M undefined-25.43 M undefined
201623.04 M undefined-19.49 M undefined-18.61 M undefined
201529.12 M undefined-2.22 M undefined-149,000 undefined
201426.63 M undefined1.84 M undefined-2.28 M undefined
201332.42 M undefined7.12 M undefined7.14 M undefined

Molecular Partners Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
3226292320102099189757204582218361
--18.7511.54-20.69-13.04-50.00100.00-55.00-2,000.00-96.30-28.5740.00185.71125.0082.22165.8565.60
96.88100.0093.1095.6595.0080.00100.0088.89100.0099.47100.00-------
31262722198208918870000000
71-2-19-25-37-36-58-63116-61-68-78-75-68-49135187
21.883.85-6.90-82.61-125.00-370.00-180.00-644.44-700.0061.38-871.43-1,360.00-1,114.29-375.00-151.11-59.7661.9351.80
7-20-18-25-37-36-62-63117-61-66-75-72-63-4314131
--128.57--38.8948.00-2.7072.221.61-285.71-152.148.2013.64-4.00-12.50-31.75-132.56835.71
19.319.319.5420.4320.8621.1721.412531.0132.4732.770000000
------------------
Details

Keystats

Revenue and Growth

The Molecular Partners Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Molecular Partners is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20132014201520162017201820192020202120222023
                     
96.1188.4215.39180.23141.0698.9695.08173.72132.81249.14186.89
11.42.90.880.080.2149.320.230.1623.791.21.43
0.10.30.470.770.952.292.322.681.940.51.66
00000000000
0.10.40.130.490.312.752.291.255.653.912.49
107.7192216.86181.56142.53153.3299.92177.81164.19254.75192.46
2.322.522.51.871.464.249.398.157.245.68
00000000000
000000001.9910
0017.474727382772347331271212
00000000000
00000000000
2.322.542.541.91.845.019.7310.478.515.89
110194219.4184.1144.42155.16104.94187.55174.66263.26198.35
                     
1.521.962.072.12.122.162.923.233.63.64
66.5167169.14171.14175.35179.44182.85299.48355.01360.32365.53
-14.1-17.3-18.02-37.27-60.72-89.86-130.87-195.17-250.95-127.78-191.76
00000000000
00000000000
53.9151.7153.09135.95116.7391.754.14107.22107.29236.15177.41
0.20.31.231.030.722.112.022.84.8610.41
43.23.064.264.556.927.0110.7412.58.658.47
18.518.522.1510.488.8827.8318.3142.9528.316.414.33
00000000000
0000001.271.181.191.21.21
22.72226.4515.7714.1436.8728.6157.6746.8717.2514.42
0000001.286.044.853.652.44
00000000000
39.123.441.1532.5413.5526.5920.9116.6213.666.195.06
39.123.441.1532.5413.5526.5922.1922.6618.519.847.51
61.845.467.648.327.6963.4550.880.3365.3827.0921.92
115.7197.1220.69184.25144.42155.16104.93187.55172.67263.24199.33
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Molecular Partners provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Molecular Partners's financial health and stability.

Assets

Molecular Partners's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Molecular Partners must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Molecular Partners after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Molecular Partners's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
7-20-18-25-37-36-62-63117-61
00011022222
00000000000
-11731003022-35-6-6
-10-1721-18-15-628546
00000000000
00000000000
-13-1126-35-40-42-1-28-90118-59
-10-1-100-1-1-1-10
-10-20-11209-19-21-22-10144
00-19-102110-17-20-20-9945
00000000000
000000-1-1-1-1-1
-2101000011145100
-21010000011350-1-1
-----------
00000000000
-17926-45-18-32-2358-6116-20
-15.06-11.8425.13-36.48-40.52-43.34-3.05-30.67-92.26117.15-59.81
00000000000

Molecular Partners stock margins

The Molecular Partners margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Molecular Partners. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Molecular Partners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Molecular Partners's sales revenue. A higher gross margin percentage indicates that the Molecular Partners retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Molecular Partners's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Molecular Partners's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Molecular Partners's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Molecular Partners. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Molecular Partners's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Molecular Partners Margin History

Molecular Partners Gross marginMolecular Partners Profit marginMolecular Partners EBIT marginMolecular Partners Profit margin
2030e99.86 %51.74 %36.36 %
2029e99.86 %62.35 %6.7 %
2028e99.86 %-60.5 %-53.07 %
2027e99.86 %-150 %-139.54 %
2026e99.86 %-377.8 %-362.44 %
2025e99.86 %-1,050 %-1,012.18 %
2024e99.86 %-1,182.35 %-1,144.11 %
202399.86 %-868.26 %-880.7 %
202299.47 %61.5 %62.16 %
202199.38 %-650.17 %-653.94 %
202093.99 %-624.21 %-671.7 %
201999.75 %-179.86 %-178.03 %
201879.7 %-361.27 %-357.66 %
201799.7 %-129.12 %-127.05 %
201699.74 %-84.57 %-80.78 %
201596 %-7.62 %-0.51 %
201499.32 %6.91 %-8.56 %
201396.24 %21.96 %22.02 %

Molecular Partners Stock Sales Revenue, EBIT, Earnings per Share

The Molecular Partners earnings per share therefore indicates how much revenue Molecular Partners has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Molecular Partners earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Molecular Partners's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Molecular Partners’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Molecular Partners's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Molecular Partners Revenue, EBIT and net profit per share

DateMolecular Partners Sales per ShareMolecular Partners EBIT per shareMolecular Partners Earnings per Share
2030e9.81 undefined0 undefined3.57 undefined
2029e5.92 undefined0 undefined0.4 undefined
2028e2.24 undefined0 undefined-1.19 undefined
2027e1.24 undefined0 undefined-1.73 undefined
2026e0.54 undefined0 undefined-1.97 undefined
2025e0.2 undefined0 undefined-2.06 undefined
2024e0.16 undefined0 undefined-1.8 undefined
20230.21 undefined-1.86 undefined-1.89 undefined
20225.84 undefined3.59 undefined3.63 undefined
20210.31 undefined-2.05 undefined-2.06 undefined
20200.37 undefined-2.33 undefined-2.51 undefined
20190.95 undefined-1.71 undefined-1.69 undefined
20180.49 undefined-1.77 undefined-1.75 undefined
20170.96 undefined-1.24 undefined-1.22 undefined
20161.13 undefined-0.95 undefined-0.91 undefined
20151.49 undefined-0.11 undefined-0.01 undefined
20141.38 undefined0.1 undefined-0.12 undefined
20131.68 undefined0.37 undefined0.37 undefined

Molecular Partners business model

Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years. Molecular Partners is one of the most popular companies on Eulerpool.com.

Molecular Partners SWOT Analysis

Strengths

Molecular Partners AG has several key strengths that contribute to its success and competitive edge. Firstly, the company has a strong and experienced management team with deep industry expertise. This ensures effective decision-making and strategic planning. Secondly, Molecular Partners AG has a diverse and innovative product portfolio, with a focus on developing novel protein therapies. This allows the company to cater to different medical needs and target a wide range of diseases. Lastly, the company has established strong partnerships with leading pharmaceutical companies, which enables it to access additional resources, expertise, and distribution channels.

Weaknesses

Despite its strengths, Molecular Partners AG also faces certain weaknesses that may hinder its growth and market position. One major weakness is the company's dependency on a limited number of product candidates. This increases its vulnerability to potential failures or setbacks in the development process. Additionally, the company may lack sufficient financial resources to independently fund its research and development activities, forcing it to rely heavily on partnerships and funding agreements. Moreover, Molecular Partners AG operates in a highly competitive industry, which could pose challenges in terms of market share and pricing.

Opportunities

There are several opportunities that Molecular Partners AG can explore to drive its growth and expand its market presence. Firstly, the increasing global demand for innovative and effective therapies provides a favorable market environment for the company to introduce and commercialize its product candidates. Secondly, the growing prevalence of various diseases, such as cancer and autoimmune disorders, offers opportunities to target unmet medical needs. Molecular Partners AG can leverage its expertise in protein therapies to develop breakthrough treatments for these conditions. Additionally, expanding into new geographic markets and collaborating with emerging biopharmaceutical companies can broaden the company's customer base and diversify its revenue streams.

Threats

Molecular Partners AG operates in an industry that is subject to various threats that may impact its business operations and profitability. Firstly, regulatory uncertainties and changing compliance requirements pose risks to the company's product development and commercialization efforts. Non-compliance or delays in obtaining necessary approvals could result in significant setbacks and increased costs. Secondly, intellectual property infringement or challenges from competitors could jeopardize Molecular Partners AG's ability to protect its proprietary technologies and product candidates. In addition, fluctuations in currency exchange rates and economic uncertainties may affect the company's financial performance, especially if it relies on international markets.

Molecular Partners Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Molecular Partners historical P/E ratio, EBIT multiple, and P/S ratio

Molecular Partners shares outstanding

The number of shares was Molecular Partners in 2023 — This indicates how many shares 32.771 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Molecular Partners earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Molecular Partners's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Molecular Partners’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Molecular Partners's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Molecular Partners.

Molecular Partners latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.43  (0 %)2024 Q2
12/31/2023-0.6  (0 %)2023 Q4
9/30/2021-0.56 -0.38  (32.26 %)2021 Q3
9/30/2016-0.32 -0.25  (20.94 %)2016 Q3
3/31/2016-0.21 -0.21  (1.96 %)2016 Q1
1

Eulerpool ESG Scorecard© for the Molecular Partners stock

Eulerpool World ESG Rating (EESG©)

74/ 100

🌱 Environment

80

👫 Social

99

🏛️ Governance

44

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Molecular Partners shareholders

%
Name
Stocks
Change
Date
23.60726 % BVF Partners L.P.8,696,205012/31/2023
5.23298 % UBS Asset Management (Switzerland)1,927,6741,055,0164/30/2024
4.75066 % Suvretta Capital Management, LLC1,750,000012/31/2023
4.72115 % Novartis AG1,739,130012/31/2023
2.77472 % GAM Investment Management (Switzerland) AG1,022,12307/31/2024
2.08357 % Stumpp (Michael Tobias)767,52410,48012/31/2023
1.99553 % Amstutz (Patrick)735,09539,17512/31/2023
1.15987 % UBS Fund Management (Switzerland) AG427,26209/30/2024
1.12960 % Union Bancaire Priv¿e416,111-3,7886/30/2024
0.92385 % Z¿rcher Kantonalbank (Asset Management)340,31910,7987/31/2024
1
2
3
4
5
...
6

Molecular Partners Executives and Management Board

Dr. Patrick Amstutz(46)
Molecular Partners Chief Executive Officer, Executive Director, Member of the Management Board (since 2006)
Compensation 1.01 M
Mr. William Burns(73)
Molecular Partners Non-Executive Independent Chairman of the Board
Compensation 295,000
Dr. Steven Holtzman(67)
Molecular Partners Non-Executive Independent Director
Compensation 135,000
Dr. Michael Vasconcelles
Molecular Partners Non-Executive Independent Director
Compensation 135,000
Mr. Sandip Kapadia(52)
Molecular Partners Non-Executive Independent Director
Compensation 130,000
1
2
3

Most common questions regarding Molecular Partners

What values and corporate philosophy does Molecular Partners represent?

Molecular Partners AG represents a strong focus on innovation, collaboration, and scientific excellence. The company is dedicated to the development of innovative therapies based on its proprietary DARPin platform. With a commitment to addressing unmet medical needs, Molecular Partners AG strives to partner with leading pharmaceutical companies and advance the discovery and development of novel treatments. The company's corporate philosophy emphasizes a patient-centric approach, aiming to improve the lives of individuals by delivering transformative therapies. By harnessing the power of protein engineering, Molecular Partners AG aims to create breakthrough medicines and make a positive impact on healthcare.

In which countries and regions is Molecular Partners primarily present?

Molecular Partners AG, a leading biotechnology company, is primarily present in several countries and regions worldwide. The company has a prominent presence in Switzerland, as it is based in Zurich. Additionally, Molecular Partners AG has established a strong foothold in Europe, including the European Union member states. Its global presence extends to the United States, with activities and collaborations in the biotech hub of Boston. With an expanding network and growing collaborations, Molecular Partners AG is well-positioned to serve and operate in various countries and regions, enabling it to contribute to the advancement of innovative biopharmaceutical solutions.

What significant milestones has the company Molecular Partners achieved?

Molecular Partners AG has achieved several significant milestones in its journey. The company has successfully advanced its proprietary DARPin platform, leading to strategic partnerships with renowned pharmaceutical companies. With a focus on developing innovative therapeutics, Molecular Partners has witnessed notable achievements, including the initiation of clinical trials for its lead oncology asset, MP0250. The company has also made progress in its ophthalmology pipeline, with the start of clinical studies for its candidate, abicipar. Additionally, Molecular Partners has gained global recognition through collaborations with key industry players, establishing a solid foundation for its continued growth and success.

What is the history and background of the company Molecular Partners?

Molecular Partners AG is a Swiss biotechnology company specializing in the development of innovative therapeutic proteins known as DARPin®s. It was established in 2004 by Christian Zahnd, Michael Stumpp, and Andreas Plückthun. Molecular Partners has a strong scientific foundation in protein engineering and has collaborated with leading pharmaceutical companies globally. The company's DARPin® platform offers advantages over conventional therapeutic approaches, including high specificity, low immunogenicity, and extended half-life. Molecular Partners has a diverse pipeline targeting multiple diseases, including oncology, ophthalmology, and infectious diseases. With a commitment to advancing patient care, Molecular Partners AG continues to leverage its expertise in protein engineering to develop innovative therapies that address unmet medical needs.

Who are the main competitors of Molecular Partners in the market?

The main competitors of Molecular Partners AG in the market are large biopharmaceutical companies such as Roche Holding AG, Novartis AG, and Pfizer Inc. These companies also focus on developing innovative biologic therapies and have a broader range of resources and expertise. However, Molecular Partners AG distinguishes itself by its novel DARPin technology, which provides advantages in terms of specificity, safety, and ease of manufacturing. This unique technology sets Molecular Partners AG apart from its competitors and positions it as a leading player in the biopharmaceutical industry.

In which industries is Molecular Partners primarily active?

Molecular Partners AG is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Molecular Partners?

The business model of Molecular Partners AG revolves around its innovative biotechnology platform, DARPin®. This platform enables the development of differentiated therapeutic candidates, leveraging the targeted nature and multi-specificity of DARPins®. By pioneering the development of DARPins®, Molecular Partners AG aims to address unmet medical needs and create value for patients, physicians, and partners. Through collaborations, licensing agreements, and partnerships, the company seeks to advance its drug candidates across various therapeutic areas, including oncology, ophthalmology, and immunology. Molecular Partners AG's business model focuses on harnessing the potential of DARPins® to deliver effective and precise treatment options for patients worldwide.

What is the P/E ratio of Molecular Partners 2024?

The Molecular Partners P/E ratio is -2.67.

What is the P/S ratio of Molecular Partners 2024?

The Molecular Partners P/S ratio is 30.56.

What is the Quality Investing of Molecular Partners?

The Quality Investing for Molecular Partners is 1/10.

What is the revenue of Molecular Partners 2024?

The expected Molecular Partners revenue is 5.78 M CHF.

How high is the profit of Molecular Partners 2024?

The expected Molecular Partners profit is -66.13 M CHF.

What is the business model of Molecular Partners

Molecular Partners AG is a biotech company specializing in the development of therapeutics with multi-specificity. The company was founded in 2004 and is headquartered in Zurich, Switzerland. The business model of Molecular Partners is based on the development of innovative therapeutics based on the DARPin technology (Designed Ankyrin Repeat Proteins). These are artificially produced proteins that specifically bind to certain target structures in tumor cells or inflammation sites. By using multi-specificity, Molecular Partners' therapeutics are able to address multiple targets simultaneously, leading to improved efficacy and safety. Molecular Partners' portfolio currently includes several drug candidates in various stages of development. The main candidate is MP0250, a multi-specific antibody conjugate (SMAC) for the treatment of solid tumors. MP0250 is currently in Phase II clinical trials and has the potential to become a new standard therapy in oncology. Another important candidate is MP0274, a multi-specific antibody conjugate for the treatment of neovascular eye diseases such as wet AMD. Preliminary results indicate that MP0274 has better efficacy and longer duration of action than the current standard of treatment. In addition, Molecular Partners has partnerships with various pharmaceutical companies, including Amgen, Novartis, and Allergan, to develop innovative therapeutics together. Molecular Partners also collaborates with the biotech company AGC Biologics to improve its production technologies and bring its drug candidates to the market faster and more efficiently. Furthermore, the company also offers services in the field of protein design. It provides its customers with the opportunity to create and produce custom proteins based on the DARPin technology. These services are tailored to the biotech and pharmaceutical sectors and have the potential to generate significant scientific advances and product pipeline developments in national and international customer programs. Molecular Partners' business model is focused on close collaboration with its customers, partners, and stakeholders. The company relies on a stringent, science-based, and agile development strategy aimed at identifying and validating promising drug candidates. In this way, Molecular Partners aims to maintain and expand a strong position in the biotech market in the long term. In summary, Molecular Partners AG is an innovative biopharmaceutical company that has a strong focus on the development of multi-specific antibody conjugates (SMAC). The company relies on a stringent, science-based, and agile development strategy to bring its drug candidates to the market quickly and efficiently. Through collaboration with partners and customers in the national and international arena, as well as the provision of custom proteins, the company aims to sustainably strengthen its position in the biotech industry.

What is the Molecular Partners dividend?

Molecular Partners pays a dividend of 0 CHF distributed over payouts per year.

How often does Molecular Partners pay dividends?

The dividend cannot currently be calculated for Molecular Partners or the company does not pay out a dividend.

What is the Molecular Partners ISIN?

The ISIN of Molecular Partners is CH0256379097.

What is the Molecular Partners WKN?

The WKN of Molecular Partners is A12DEH.

What is the Molecular Partners ticker?

The ticker of Molecular Partners is MOLN.SW.

How much dividend does Molecular Partners pay?

Over the past 12 months, Molecular Partners paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Molecular Partners is expected to pay a dividend of 0 CHF.

What is the dividend yield of Molecular Partners?

The current dividend yield of Molecular Partners is .

When does Molecular Partners pay dividends?

Molecular Partners pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Molecular Partners?

Molecular Partners paid dividends every year for the past 0 years.

What is the dividend of Molecular Partners?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Molecular Partners located?

Molecular Partners is assigned to the 'Health' sector.

Wann musste ich die Aktien von Molecular Partners kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Molecular Partners from 11/5/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Molecular Partners pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Molecular Partners in the year 2023?

In the year 2023, Molecular Partners distributed 0 CHF as dividends.

In which currency does Molecular Partners pay out the dividend?

The dividends of Molecular Partners are distributed in CHF.

All fundamentals about Molecular Partners

Our stock analysis for Molecular Partners Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Molecular Partners Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.